Faktor Risiko Terjadinya Sindrom Burnout pada Perawat di Berbagai Jenis Pelayanan
DOI:
https://doi.org/10.32583/pskm.v13i3.1259Keywords:
sindrom burnout, tinjauan sistematis, faktor risiko, perawatAbstract
Burnout adalah sindrom tiga dimensi yang terjadi pada tenaga profesional yang bekerja untuk publik, seperti profesional kesehatan. Penelitian melaporkan bahwa burnout meningkatkan jumlah kesalahan di tempat kerja, mengurangi kualitas dan keamanan perawatan, dan tingkat cuti sakit yang dapat berakibat pada penelantaran profesi. Tinjauan sistematis bertujuan memberikan informasi faktor resiko burnout pada perawat berdasarkan jenis layanan dan spesialisasi keperawatan yang berbega, hal ini berguna untuk mendeteksi dan mengetahui apakah faktor penyebab burnout itu dipengaruhi oleh jenis layanan dan keilmuan seorang perawat atau ada faktor konsisten yang akan menjadi pemicu burnout di semua jenis layanan keperawatan. Metode penelitian pada artikel ini adalah Systematic Review, Artikel dicari melalui basis data sejak Maret – Juli 2022 melalui database PUBMED, Science direct, dan Google Scholar. Tidak ada upaya dari penulis untuk mencari secara spesifik artikel-artikel yang tidak terpublikasi. Kata kunci yang digunakan antara lain: “burnout” yang dikombinasikan dengan “"Nurses"[Mesh]” AND “cardiology”, “neurology”, “dialysis”, “oncology”, “obstetric and gynecology”, “psychiatri”). Hasil yang didapat adalah 9 artikel yang memenuhi syarat kualitatif yang memberikan informasi faktor pe nyebab burnout pada perawat. Sebagian besar perawat dilaporkan memiliki tingkat kelelahan emosional dan depersonalisasi yang tinggi, bersama dengan prestasi atau pencapaian pribadi yang rendah. Mayoritas faktor resiko adalah variabel sosiodemografi tertentu (usia, jenis kelamin), variabel pekerjaan (kepuasan kerja dan durasi hari / jam kerja).
References
Ahmad, B. et al., (2021). Exploring the binding mechanism of PF-07321332 SARS-CoV-2 protease inhibitor through molecular dynamics and binding free energy simulations. International Journal of Molecular Sciences, 22(17).
Anon, (2022). Pfizer COVID-19 antiviral paxlovid authorised by MHRA. Pharmaceutical Journal.
Arabi, Y.M. et al., (2021). Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Medicine, 47(8), pp.867–886. Available at: https://doi.org/10.1007/s00134-021-06448-5.
Bethany Halford, (2022). How Pfizer scientists transformed an old drug lead into a COVID-19 antiviral. Chemical & Engineering News, pp.16–18.
Chen, C. et al., 2021. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Frontiers in Pharmacology, 12.
Cozzupoli, G.M. et al., (2020). Possible Retinal Impairment Secondary to Ritonavir Use in SARS-CoV-2 Patients: A Narrative Systematic Review. Journal of Ophthalmology, 2020.
Drożdżal, S. et al., (2021). An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resistance Updates, 59.
Extance, A., (2022). Covid-19: What is the evidence for the antiviral molnupiravir? The BMJ, (February 2020), pp.2020–2022.
Fishbane, S., Hirsch, J.S. & Nair, V., (2020). Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company â€TM s public news and information . , (January), pp.2020–2023.
Hammond, J. et al., (2022). Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of Medicine, 386(15), pp.1397–1408.
Hung, Y.P. et al., (2022). Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark? Antibiotics, 11(2), pp.5–11.
Jayk Bernal, A. et al., (2022). Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. New England Journal of Medicine, 386(6), pp.509–520.
Jin, Z. et al., (2020). Structure of M<sup>pro</sup> from SARS-CoV-2 and discovery of its inhibitors. Nature, 582(7811), pp.289–293. Available at: https://dx.doi.org/10.1038/s41586-020-2223-y.
Jun, C. et al., (2020). Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. Chinese Journal of Infectious Diseases, 38(0), pp.E008–E008.
Li, Y. et al., (2020). Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial. Med, 1(1), p.105–113.e4.
Liberati, A. et al., (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj, 339(jul21 1), pp.b2700–b2700. Available at: http://www.bmj.com/cgi/doi/10.1136/bmj.b2700.
Mahase, E., (2021). Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ (Clinical research ed.), 375, p.n2713.
Najjar-Debbiny, R. et al., (2022). Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients. Clinical Infectious Diseases, pp.1–8.
Nojomi, M. et al., (2020). Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. BMC Infectious Diseases, 20(1).
Owen, D.R. et al., (2021). An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science, 374(6575), pp.1586–1593.
Pfizer, (2021). Pfizer’s Novel Covid-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization or Death by 89% In Interim Analysis of Business Wire, Nov 10, 20, pp.1–7.
Singh, R.S.P. et al., (2022). Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir. Clinical Pharmacology and Therapeutics, 112(1), pp.101–111.
Suminanto, S., Widiyanto, A., Handayani, R. T., Kuntari, S., Darmayanti, A. T., & Atmojo, J. T. (2021). Strategi Koping Tenaga Kesehatan selama Pandemi Covid-19. Jurnal Ilmu Keperawatan Jiwa, 4(1), 141-148.
Widiyanto, A., Kurniawan, H., Handayani, A. F., Duarsa, A. B. S., Anulus, A., Anasulfalah, H., ... & Livana, P. H. (2022). Pengaruh Telehealth terhadap Penurunan Derajat Depresi pada Pasien Stroke: Meta-Analisis. Jurnal Keperawatan, 14(3), 609-618.
Wu, F. et al., (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), pp.265–269.
Zhu, Z. et al., (2020). Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. Journal of Infection, 81(1), pp.e21–e23
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Jurnal Ilmiah Permas: Jurnal Ilmiah STIKES Kendal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
